PAX2 Protein Induces Expression of Cyclin D1 through Activating AP-1 Protein and Promotes Proliferation of Colon Cancer Cells*

Background: PAX2, a transcription factor, plays a role in embryogenesis. Results: Knockdown of PAX2 inhibits colon cancer cells proliferation and xenograft growth. PAX2 activates AP-1, leading to increased expression of cyclin D1. Conclusion: PAX2 promotes proliferation of colon cancer cells via AP-1. Significance: PAX2 exhibits oncogenic properties in colon cancer cells and may serve as a target for cancer therapy. Paired box (PAX) 2, a transcription factor, plays a critical role in embryogenesis. When aberrantly expressed in adult tissues, it generally exhibits oncogenic properties. However, the underlying mechanisms remain unclear. We reported previously that the expression of PAX2 was up-regulated in human colon cancers. However, the role of PAX2 in colon cancer cells has yet to be determined. The aim of this study is to determine the function of PAX2 in colon cancer cells and to investigate the possible mechanisms underlain. We find that knockdown of PAX2 inhibits proliferation and xenograft growth of colon cancer cells. Inhibition of PAX2 results in a decreased expression of cyclin D1. Expression of cyclin D1 is found increased in human primary colon malignant tumors, and its expression is associated with that of PAX2. These data indicate that PAX2 is a positive regulator of expression of cyclin D1. We find that knockdown of PAX2 inhibits the activity of AP-1, a transcription factor that induces cyclin D1 expression, implying that PAX2 induces cyclin D1 through AP-1. PAX2 has little effect on expression of AP-1 members including c-Jun, c-Fos, and JunB. Our data show that PAX2 prevents JunB from binding c-Jun and enhances phosphorylation of c-Jun, which may elevate the activity of AP-1. Taken together, these results suggest that PAX2 promotes proliferation of colon cancer cells through AP-1.

[1]  M. Karin,et al.  Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun , 1989, Cell.

[2]  H. Iwao,et al.  AP-1 and colorectal cancer , 2006, InflammoPharmacology.

[3]  Andre C. Eaddy,et al.  Inhibition of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status. , 2007, Cancer letters.

[4]  C. Albanese,et al.  The cyclin D 1 gene is a target of the b-catenin y LEF-1 pathway , 1999 .

[5]  B. Spencer‐Dene,et al.  JNK signalling modulates intestinal homeostasis and tumourigenesis in mice , 2009, The EMBO journal.

[6]  Claus Scheidereit,et al.  NF-κB Function in Growth Control: Regulation of Cyclin D1 Expression and G0/G1-to-S-Phase Transition , 1999, Molecular and Cellular Biology.

[7]  M. Eccles,et al.  Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival , 2003, Oncogene.

[8]  S. Reddy,et al.  Role and regulation of activator protein-1 in toxicant-induced responses of the lung. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[9]  James R. Woodgett,et al.  Phosphorylation of c-jun mediated by MAP kinases , 1991, Nature.

[10]  Xianglin Shi,et al.  Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. , 2006, Carcinogenesis.

[11]  J. Minna,et al.  jun-B inhibits and c-fos stimulates the transforming and trans-activating activities of c-jun , 1989, Cell.

[12]  B. Ruggeri,et al.  PAX genes: roles in development, pathophysiology, and cancer. , 2007, Biochemical pharmacology.

[13]  Frank McCormick,et al.  β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.

[14]  Zhao-dong Li,et al.  Forkhead Transcription Factor FOXO3a Protein Activates Nuclear Factor κB through B-cell lymphoma/leukemia 10 (BCL10) Protein and Promotes Tumor Cell Survival in Serum Deprivation* , 2012, The Journal of Biological Chemistry.

[15]  N. Coleman,et al.  Colorectal cancer screening: prospects for molecular stool analysis , 2005, Nature Reviews Cancer.

[16]  M. Eccles,et al.  A PANorama of PAX genes in cancer and development , 2006, Nature Reviews Cancer.

[17]  Duo Zheng,et al.  Extracellular signal-regulated kinase 8-mediated c-Jun phosphorylation increases tumorigenesis of human colon cancer. , 2010, Cancer research.

[18]  Axel Behrens,et al.  Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development , 2005, Nature.

[19]  M. Karin,et al.  AP-1 as a regulator of cell life and death , 2002, Nature Cell Biology.

[20]  Hai-sheng Zhang,et al.  Prolyl hydroxylase domain protein 3 targets Pax2 for destruction. , 2011, Biochemical and biophysical research communications.

[21]  M. Karin,et al.  JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. , 1993, Genes & development.

[22]  E. Bossy‐Wetzel,et al.  Cell cycle‐dependent variations in c‐Jun and JunB phosphorylation: a role in the control of cyclin D1 expression , 2000, The EMBO journal.

[23]  E. Wagner,et al.  AP-1 in mouse development and tumorigenesis , 2001, Oncogene.

[24]  H. Moch,et al.  Loss of VHL and Hypoxia Provokes PAX2 Up-Regulation in Clear Cell Renal Cell Carcinoma , 2009, Clinical Cancer Research.

[25]  C. Albanese,et al.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Jing Fang,et al.  Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. , 2010, Gastroenterology.

[27]  M. Dyer,et al.  The search for the retinoblastoma cell of origin , 2005, Nature Reviews Cancer.

[28]  M. Eccles,et al.  PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells. , 2006, Kidney international.

[29]  J. Gnarra,et al.  Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. , 1995, Cancer research.

[30]  H. Mizuguchi,et al.  Dominant-negative mutant of c-Jun gene transfer: a novel therapeutic strategy for colorectal cancer , 2004, Gene Therapy.

[31]  H. Nishimatsu,et al.  Transcriptional Activation of the cyclin D1 Gene Is Mediated by Multiple Cis-Elements, Including SP1 Sites and a cAMP-responsive Element in Vascular Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[32]  G. Landberg,et al.  Expression of cyclin D1 and retinoblastoma protein in colorectal cancer. , 1998, European journal of cancer.

[33]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[34]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[35]  M. Eccles,et al.  In vivo validation of PAX2 as a target for renal cancer therapy. , 2008, Cancer letters.

[36]  M. Eccles,et al.  PAX2 suppresses apoptosis in renal collecting duct cells. , 2000, The American journal of pathology.

[37]  C. Albanese,et al.  Transforming p21ras Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions (*) , 1995, The Journal of Biological Chemistry.

[38]  G. Landberg,et al.  Human colorectal cancers with an intact p16/cyclin D1/pRb pathway have up-regulated p16 expression and decreased proliferation in small invasive tumor clusters. , 2000, The American journal of pathology.

[39]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.

[40]  Michael Karin,et al.  Oncogene at last--c-Jun promotes liver cancer in mice. , 2003, Cancer cell.

[41]  M. Bissonnette,et al.  Elevated protein expression of cyclin D1 and Fra‐1 but decreased expression of c‐Myc in human colorectal adenocarcinomas overexpressing β‐catenin , 2002, International journal of cancer.

[42]  N. Colburn,et al.  AP-1 a target for cancer prevention. , 2007, Current cancer drug targets.

[43]  H. Hibshoosh,et al.  Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. , 1996, Gastroenterology.

[44]  P. Cassoni,et al.  Role of Pax2 in Apoptosis Resistance and Proinvasive Phenotype of Kaposi's Sarcoma Cells* , 2004, Journal of Biological Chemistry.